Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will release its third quarter 2025 financial results and operational highlights before U.S. market open on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30 AM EST / 1:30 PM GMT to discuss results and provide a business update. Participants must pre-register to receive dial-in numbers and a personal PIN required for access. A simultaneous audio webcast and a replay will be available from the events section of Autolus’ investor website.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, AUTL gained 3.42%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $411M at that time.
Data tracked by StockTitan Argus on the day of publication.
LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, 2025.
Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
When will Autolus (AUTL) release Q3 2025 results and hold the conference call?
How can investors join the Autolus (AUTL) November 12, 2025 conference call?
Will Autolus (AUTL) provide a webcast or replay of the November 12, 2025 call?
What topics will Autolus (AUTL) cover on the November 12, 2025 call?
What time is the Autolus (AUTL) webcast available in GMT on November 12, 2025?
Where can I find dial-in details and the webcast link for Autolus (AUTL)?
